Floatz logo

Palbociclib

Advanced Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

288 Active assets in the Advanced Lymphoma cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
(+)-VINCRISTINE
Beth Israel Deaconess Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →